PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes.

Front Med (Lausanne) · 2026 · PMC12999965 · PMID 41868208

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

showed a trendP > 0.05actually significant

Regarding fibrosis indicators, although PCSK9i use showed a trend toward improvement in Δ APRI (β = −0.021) and Δ FIB-4 (β = −0.19), these associations did not reach statistical significance in the adjusted model ( P > 0.05).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.